Christina Curtis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7260348/publications.pdf

Version: 2024-02-01

71102 64796 17,303 84 41 79 citations h-index g-index papers 105 105 105 29769 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Molecular Cancer Research, 2022, 18, 599-611.	3.4	56
2	Patient perspectives on window of opportunity clinical trials in early-stage breast cancer. Breast Cancer Research and Treatment, 2022, , 1.	2.5	0
3	The Mettl3 epitranscriptomic writer amplifies p53 stress responses. Molecular Cell, 2022, 82, 2370-2384.e10.	9.7	22
4	Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nature Genetics, 2022, 54, 985-995.	21.4	77
5	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature Communications, 2022, 13, .	12.8	21
6	Molecular Heterogeneity and Evolution in Breast Cancer. Annual Review of Cancer Biology, 2021, 5, 79-94.	4.5	14
7	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. Cancers, 2021, 13, 316.	3.7	16
8	Androgen receptor agonists as breast cancer therapeutics. Nature Medicine, 2021, 27, 198-199.	30.7	7
9	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nature Communications, 2021, 12, 1920.	12.8	19
10	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	28.9	135
11	Cell of Origin Influences Pancreatic Cancer Subtype. Cancer Discovery, 2021, 11, 660-677.	9.4	58
12	The AMBRA1 E3 ligase adaptor regulates the stability of cyclinÂD. Nature, 2021, 592, 794-798.	27.8	76
13	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nature Cancer, 2021, 2, 400-413.	13.2	41
14	A tumor "personality―test to guide therapeutic decision making. Cancer Cell, 2021, 39, 747-749.	16.8	2
15	Transcriptome and genome evolution during HER2-amplified breast neoplasia. Breast Cancer Research, 2021, 23, 73.	5.0	2
16	Abstract 123: A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and non-essential modes of oncogenic transformation., 2021,,.		1
17	Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature, 2021, 597, 549-554.	27.8	95
18	Preface. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188617.	7.4	0

#	Article	IF	CITATIONS
19	A CRISPR/Cas9-Engineered <i>ARID1A</i> -Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation. Cancer Discovery, 2021, 11, 1562-1581.	9.4	75
20	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 2020, 11, 5824.	12.8	42
21	Characterizing the ecological and evolutionary dynamics of cancer. Nature Genetics, 2020, 52, 759-767.	21.4	77
22	The m ⁶ A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21441-21449.	7.1	56
23	Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Molecular Cell, 2020, 80, 452-469.e9.	9.7	44
24	Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature Genetics, 2020, 52, 701-708.	21.4	203
25	CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature, 2020, 580, 136-141.	27.8	203
26	Quantifying mutations in healthy blood. Science, 2020, 367, 1426-1427.	12.6	4
27	Looking backward in time to define the chronology of metastasis. Nature Communications, 2020, 11, 3213.	12.8	39
28	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
29	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 2020, 31, 745-759.	1.2	770
30	Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing. ELife, 2020, 9, .	6.0	47
31	Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine, 2019, 25, 1251-1259.	30.7	974
32	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	21.4	315
33	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 2019, 567, 399-404.	27.8	239
34	Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications, 2019, 10, 657.	12.8	43
35	Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nature Medicine, 2019, 25, 1721-1727.	30.7	27
36	Assessment of <i>ERBB2 </i> / <i>HER2 </i> Status in <i <="" her2="" i="">/i>-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology, 2019, 5, 366.</i>	7.1	26

#	Article	IF	CITATIONS
37	Promoter of IncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cell, 2018, 173, 1398-1412.e22.	28.9	362
38	Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nature Genetics, 2018, 50, 483-486.	21.4	101
39	Big Bang Tumor Growth and Clonal Evolution. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a028381.	6.2	38
40	The chromatin accessibility landscape of primary human cancers. Science, 2018, 362, .	12.6	781
41	A role for chromatin regulatory dynamics in breast cancer evolution. Nature Medicine, 2018, 24, 1309-1311.	30.7	2
42	Quantification of subclonal selection in cancer from bulk sequencing data. Nature Genetics, 2018, 50, 895-903.	21.4	222
43	Organoids reveal cancer dynamics. Nature, 2018, 556, 441-442.	27.8	16
44	Harnessing Tumor Evolution to Circumvent Resistance. Trends in Genetics, 2018, 34, 639-651.	6.7	49
45	Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells. Cancer Research, 2017, 77, 1575-1585.	0.9	94
46	A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 109-126.	7.4	37
47	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell, 2017, 32, 460-473.e6.	16.8	142
48	Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity. Cell Stem Cell, 2017, 21, 78-90.e6.	11.1	280
49	Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nature Genetics, 2017, 49, 1015-1024.	21.4	144
50	Early mutation bursts in colorectal tumors. PLoS ONE, 2017, 12, e0172516.	2.5	1
51	Population Genetics Approaches to Quantify Clonal Evolution. Blood, 2017, 130, SCI-37-SCI-37.	1.4	0
52	Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research, 2016, 18, 70.	5.0	11
53	Inferring Tumor Phylogenies from Multi-region Sequencing. Cell Systems, 2016, 3, 12-14.	6.2	12
54	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC) Journal of Clinical Oncology, 2016, 34, 1010-1010.	1.6	0

#	Article	IF	CITATIONS
55	Many private mutations originate from the first few divisions of a human colorectal adenoma. Journal of Pathology, 2015, 237, 355-362.	4.5	30
56	Genomic profiling of breast cancers. Current Opinion in Obstetrics and Gynecology, 2015, 27, 34-39.	2.0	19
57	A Big Bang model of human colorectal tumor growth. Nature Genetics, 2015, 47, 209-216.	21.4	867
58	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 2015, 9, 115-127.	4.6	38
59	Contributions to Drug Resistance in Glioblastoma Derived from Malignant Cells in the Sub-Ependymal Zone. Cancer Research, 2015, 75, 194-202.	0.9	48
60	Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biology, 2014, 15, 431.	8.8	178
61	The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31. Molecular Cell, 2014, 53, 806-818.	9.7	55
62	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4009-4014.	7.1	1,471
63	Single-Molecule Genomic Data Delineate Patient-Specific Tumor Profiles and Cancer Stem Cell Organization. Cancer Research, 2013, 73, 41-49.	0.9	68
64	The shaping and functional consequences of the microRNA landscape in breast cancer. Nature, 2013, 497, 378-382.	27.8	370
65	Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling. PLoS Computational Biology, 2013, 9, e1003047.	3.2	76
66	Precise inference of copy number alterations in tumor samples from SNP arrays. Bioinformatics, 2013, 29, 2964-2970.	4.1	12
67	Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer. Science Translational Medicine, 2013, 5, 181re1.	12.4	108
68	Abstract 5016: The human sub-ependymal zone harbors glioblastoma precursors and represents a distinct therapeutic target Cancer Research, 2013, 73, 5016-5016.	0.9	21
69	Abstract SY36-01: Exploiting intra-tumor heterogeneity through agent-based models of tumor growth to infer properties of human malignancies , 2013, , .		0
70	Abstract B020: A copy number and expression based classifier for breast cancer tumors., 2013,,.		0
71	Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling. Science Translational Medicine, 2012, 4, 157ra143.	12.4	356
72	Calling Sample Mix-Ups in Cancer Population Studies. PLoS ONE, 2012, 7, e41815.	2.5	6

#	Article	IF	CITATIONS
73	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.	27.8	4,708
74	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	27.8	1,778
75	<i>ZNF703</i> is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Molecular Medicine, 2011, 3, 167-180.	6.9	119
76	The importance of platform annotation in interpreting microarray data. Lancet Oncology, The, 2010, 11 , 717 .	10.7	14
77	A sparse regulatory network of copy-number driven expression reveals putative breast cancer oncogenes., 2010,,.		2
78	Swift: primary data analysis for the Illumina Solexa sequencing platform. Bioinformatics, 2009, 25, 2194-2199.	4.1	83
79	The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics, 2009, 10, 588.	2.8	80
80	Product Length, Dye Choice, and Detection Chemistry in the Bead-Emulsion Amplification of Millions of Single DNA Molecules in Parallel. Analytical Chemistry, 2009, 81, 5770-5776.	6.5	15
81	A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging, 2009, 1, 191-211.	3.1	52
82	Drosophila melanogaster p53 has developmental stage-specific and sex-specific effects on adult life span indicative of sexual antagonistic pleiotropy. Aging, 2009, 1, 903-936.	3.1	58
83	Explaining differences in saturation levels for Affymetrix GeneChip® arrays. Nucleic Acids Research, 2007, 35, 4154-4163.	14.5	37
84	Transcriptional profiling of MnSOD-mediated lifespan extension in Drosophila reveals a species-general network of aging and metabolic genes. Genome Biology, 2007, 8, R262.	9.6	123